PMID- 28698845
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2287-979X (Print)
IS  - 2288-0011 (Electronic)
IS  - 2287-979X (Linking)
VI  - 52
IP  - 2
DP  - 2017 Jun
TI  - Intrachromosomal amplification of chromosome 21 in Korean pediatric patients with 
      B-cell precursor acute lymphoblastic leukemia in a single institution.
PG  - 100-105
LID - 10.5045/br.2017.52.2.100 [doi]
AB  - BACKGROUND: Intrachromosomal amplification of chromosome 21 (iAMP21), defined as 
      the presence of three or more RUNX1 signals on one marker chromosome, is a 
      distinct cytogenetic subgroup of childhood B-cell precursor acute lymphoblastic 
      leukemia (BCP-ALL) that is known to have a poor prognosis when treated with 
      standard therapy. The aim of this study was to evaluate the clinical 
      characteristics of Korean children with iAMP21. METHODS: The cytogenetic data 
      from BCP-ALL children were reviewed. The ETV6/RUNX1 ES Dual Color Probe was used 
      for fluorescence in situ hybridization (FISH). RESULTS: In total, 295 children 
      were included. Of these, 10 patients (3.4%) had iAMP21. The median age of iAMP21 
      patients was 9 years, and the median value of white blood cell count was 
      5.09x10(9)/L. Slow early treatment response was observed more in iAMP21 patients. 
      Patients with iAMP21 had a higher incidence of relapse and worse survival rates. 
      In patients with iAMP21, the estimated 10-year cumulative incidence of relapse 
      was 53.3%. The estimated 10-year event-free survival and overall survival rate 
      were 46.7% and 64.8%, respectively. Most cases of leukemic relapse developed in 
      the late period (median, 43 mo). In multivariate analysis, high risk group was 
      the only factor that had a significant impact on death. CONCLUSION: The existence 
      of iAMP21 was related to delayed treatment response and was likely to affect 
      increased relapse and death in the late period. Further studies are needed to 
      reveal its effect on BCP-ALL treatment outcomes and its role as an independent 
      prognostic factor.
FAU - Yang, Mina
AU  - Yang M
AD  - Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
FAU - Yi, Eun Sang
AU  - Yi ES
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Kim, Hee Jin
AU  - Kim HJ
AD  - Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
FAU - Yoo, Keon Hee
AU  - Yoo KH
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Koo, Hong Hoe
AU  - Koo HH
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Kim, Sun-Hee
AU  - Kim SH
AD  - Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20170622
PL  - Switzerland
TA  - Blood Res
JT  - Blood research
JID - 101605247
PMC - PMC5503886
OTO - NOTNLM
OT  - Childhood BCP-ALL
OT  - FISH
OT  - iAMP21
COIS- Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts 
      of interest relevant to this article were reported.
EDAT- 2017/07/13 06:00
MHDA- 2017/07/13 06:01
PMCR- 2017/06/01
CRDT- 2017/07/13 06:00
PHST- 2016/09/05 00:00 [received]
PHST- 2017/02/01 00:00 [revised]
PHST- 2017/03/13 00:00 [accepted]
PHST- 2017/07/13 06:00 [entrez]
PHST- 2017/07/13 06:00 [pubmed]
PHST- 2017/07/13 06:01 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - 10.5045/br.2017.52.2.100 [doi]
PST - ppublish
SO  - Blood Res. 2017 Jun;52(2):100-105. doi: 10.5045/br.2017.52.2.100. Epub 2017 Jun 
      22.